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Background: Experimental animal models of migraine have suggested the existence of interactions between the
endocannabinoid system and pain mediation in migraine. Extensive evidence has demonstrated a role for the
cannabinoid-1 (CB1) receptor in antinociception. However, recent research suggests that also CB2 receptors, especially
located outside the central nervous system, play a role in the perception of pain. Systemic administration of
nitroglycerin (NTG) consistently induces spontaneous-like headache attacks in migraneurs; in the rat, systemic
NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved
in nociceptive transmission. In this study we evaluated the role of CB2 receptors in two animal models of pain that
may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia.
Methods: The study was performed in male Sprague-Dawley rats pre-treated with NTG (10 mg/kg, i.p.) or vehicle
(4 hours before) and treated with the CB2 agonist AM1241 o dimethylsulfoxide (DMSO) 60 minutes before both
the tail flick test and the formalin test.
Results: AM1241 showed a significant analgesic effect in baseline conditions in both tests. Furthermore, when
administered 3 hours after NTG administration, AM1241 at both doses significantly reduced the total number of
flinches/shakes during phase II of the test.
Conclusion: These findings suggest that the pharmacological manipulation of the CB2 receptor may represent a
potential therapeutic tool for the treatment of migraine.
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Experimental evidence suggests an important role for
endocannabinoids in pain modulation. Administration of
endocannabinoids, either systemically or directed at
appropriate pain relay or modulatory sites, alters pain
sensitivity and changes the processing of nociceptive
information within discrete spinal and brain pathways.
Therefore, the discovery of endocannabinoid system has
prompted the development of a range of novel canna-
binoid receptor agonists and antagonists, some of which
show marked selectivity for CB1 or CB2 receptors. CB1
receptors are found in the central nervous system and* Correspondence: cristina.tassorelli@mondino.it
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in any medium, provided the original work is phave also been suggested to lie on peripheral nerve ter-
minals [1]. Anandamide (AEA) is a full agonist at CB1
receptors and a partial agonist at CB2 receptors. Admin-
istration of AEA into the ipsilateral hindpaw of the
rat reduced carrageenan-induced hyperalgesia [2] or
formalin-induced nociception [3], indicating that activa-
tion of peripheral CB1 receptors and in part CB2 recep-
tors, produces antinociception. CB2 receptors are mostly
located outside of the central nervous system [4,5], and
they were originally believed to be restricted to the periph-
ery, primarily in the immune system, including mast cells,
B and T cells, macrophages, and natural killer cells [6].
However, low levels of CB2 receptors were also observed
in different CNS regions, with an upregulation in sites
implicated in nociception [7,8]. Selective agonists for
CB2 receptor have been shown to produce analgesicn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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pathic, and bone cancer pain [9,10]. Recent evidence
shows that selective agonists of CB2 receptors reduce
nociception in a variety of preclinical models without
producing tolerance [11,12] or central side-effects [13],
thus suggesting that CB2 agonists may represent an
attractive therapeutic target for pain.
A deficiency of the endocannabinoid system has been
postulated to underlie the pathophysiology of migraine,
as suggested by clinical studies, although biochemical
studies providing a scientific basis for the potential effi-
cacy of endocannabinoids in migraine are so far really
limited [14]. Using a well characterized animal model of
migraine [15-18] based on the quantification of behav-
ioral (nocifensive) and neurochemical changes induced
by systemic nitroglycerin (NTG) - a vasodilator known to
induce migraine-like headache in migraineurs [19-21] - we
have gathered evidence to suggest a derangement of the
endocannabinoid function in migraine. In this frame,
NTG-induced hyperalgesia is associated with an in-
creased activity of the enzymes involved in the catabol-
ism of endocannabinoids in several brain areas and
with an increased density of CB binding sites in the
mesencephalon [22]. Additionally, AEA has proved to
be effective in preventing both NTG-induced activation
(c-Fos) of neurons in the nucleus trigeminalis caudalis
(NTC) and NTG-induced hyperalgesia at the formalin
test [23]. This model has been tested over the years
with different drugs and is generally accepted as a reli-
able animal model of migraine [15-18,24]. Several lines
of evidence suggest the existence of a condition of tri-
geminal sensitization in migraineurs, which results in
hyperalgesia, allodynia, and cognitive dysfunction during
and between episodes [25,26]. NTG is known to induce
spontaneous-like headache attacks in migraine sufferers
[16], probably as a consequence of sensitization phenom-
ena [27]. In addition, NTG administration to migraineurs
is associated to a significant facilitation in temporal sum-
mation of pain (reduced temporal summation threshold
and increased painful sensation) when compared to base-
line, to placebo condition and to controls. This finding
suggests that migraineurs bear a susceptibility to develop
migraine attack after NTG administration as a specific
trait linked to a supersensitivity of the pain system to
NTG [28]. AM1241 is a well characterized agonist of the
CB2 receptor that mediates antinociception following
systemic administration in animal models not specific for
migraine [29]. The present study is aimed at evaluating
the potential analgesic effect of AM1241 in animal models
of hyperalgesia induced by NTG administration.
Methods
Adult male Sprague-Dawley rats (weight 250-270 g,
N = 4-8 for group) were evaluated in the presentexperiments. The principles of the Helsinki declaration
and IASP’s guidelines for pain research in animals were
rigorously applied [30]. The experimental research on ani-
mals was approved by ethics committee for research on
animals of the University of Pavia (Document n. 2, 2012).
Animals were housed in plastic boxes in groups of 3 with
water and food available ad libitum and kept on a
12:12 hours light-dark cycle. All the rats were acclimatized
to the test chamber before testing began.
Drugs
AM1241 (Cayman Chemical) was injected intraperitone-
ally at two different doses: 2 and 4 mg/kg. The CB2 agon-
ist was dissolved in 100% Dimethylsulfoxide (DMSO) as
vehicle and administered in a volume of 1 ml/kg body-
weight [31] 60 minutes before the experimental tests, and
4 hours after NTG (or saline+alcohol +propylene glycol)
administration. Nitroglycerin (NTG) (Astra Company,
Italy), dissolved in saline, alcohol and propylene glycol,
was injected i.p. at a dose of 10 mg/Kg.
For the Formalin test, a 100 μl volume of 1% forma-
lin (formaldehyde diluted in 0.9% saline) was injected
intraplantarly.
Rats were randomly divided into groups formed by 5-8
animals each, and underwent either the Tail flick test or
the Formalin test. Rats were assigned to one of the
treatment group according to a randomization list,
whose codes were unblinded only after study completion.
Therefore, the researchers who performed the behavioural
testing (RG or SM) were blind to treatments.
Tail flick test
Rats in this experiment were tested for latency of reflex
tail withdrawal (Tail flick test, TFT) from a high intensity
light beam, which was considered as a measure of
physiological phasic pain.
The test was performed with a Tail Flick test instru-
ment (Ugo Basile) that allowed automatic recording of
tail-flick latency to radiant heat. Latency at each evalu-
ation was calculated as the mean of three or five mea-
surements in three different parts of the tail. A cut-off
limit of exposure corresponding to 20 s was set to pre-
vent tissue damage.
Each animal was placed on the recording platform of
the instrument where it was kept under slight, painless
restraint, with its tail positioned on the radiant heat
window. The movement of the tail from window of the
beam of light to hit a sensor was automatically registered.
Formalin test
Rats in this experiment underwent Formalin test (FT)
for the evaluation of inflammatory tonic pain.
One animal at a time was placed into a plexiglas
observation chamber (10 × 20 × 24 cm) with a mirror
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of the animal paws. Formalin was injected subcutane-
ously into the center of the plantar surface of the left
hind paw with slight restraint. A 26-gauge needle con-
nected to a 1 ml syringe was used and the solution was
delivered as rapidly as possible while the animal was
immobilized. The rat was then replaced in the box, the
clock was started and pain response was recorded for a
period of 1 h [32].
The pain–related behaviour was quantified by count-
ing the total number of flinches and shakes occurring
for 1-min periods from 1 to 5 min (Phase I) and, then
for 1-min periods at 5-min intervals during the period
from 10 to 60 min (Phase II) after formalin injection.
Phase I is generally considered the result of chemical
activation of nociceptors, while Phase II reflects the
inflammatory reaction and central processing.
Flinches/shakes were readily discriminated and were
characterized as rapid and brief withdrawal movements
or flexions of the injected paw.
Experimental groups
The experimental plan was performed according to the
treatment schedule indicated in Figure 1.
Statistical evaluation
The effects of treatments upon the latency of the TFT
were evaluated by means of the Wilcoxon rank-sum test
(baseline vs. post-treatment). A probability level of less
than 5% was regarded as significant. For FT, the total
number of flinches/shakes evoked by formalin injectionFigure 1 Experimental plan and experimental groups. TFT: tail flick tes
AM1241 Group: AM1241 (a) (2 mg/kg, i.p.) dissolved in DMSO injected i.p.;
i.p.; Control Group: vehicle (saline, alcohol and propylene glycole) injected
propylene glycole) injected i.p. at the dose of 10 mg/kg; NTG + DMSO Gr
NTG + AM1241 (a) Group: nitroglycerin (10 mg/kg, i.p.) and AM1241 (2 mg
(10 mg/kg, i.p.) and AM1241 (4 mg/kg, i.p.) administered i.p.was counted separately for phase I and for phase II, as
described above. Differences between groups were ana-
lysed by the one-way analysis of variance (ANOVA)
followed by Tukey’s Multiple Comparison test. A prob-
ability level of less than 5% was regarded as significant.
Results
Tail flick test
The vehicle used for AM1241, DMSO, did not induce
any significant effect on the tail flick latency (Figure 2).
Conversely, AM1241 (2 and 4 mg/Kg) induced signifi-
cant analgesia 60 minutes after its administration when
compared to baseline (Figure 2). NTG, either alone or in
association with DMSO, induced a hyperalgesic response
at the TFT as suggested by the significant decrease in
the latency of the tail flick response 4 hours after its
administration when compared to control group (CT).
Administration of AM1241 did not counteract NTG-
induced hyperalgesia.
Formalin test
In the two vehicle groups (DMSO and CT), the injection
of formalin resulted in a highly reliable, typical, biphasic
pattern of flinches/shakes of the injected paw, being
characterized by an initial acute phase of nociception
within the first 5 min, followed by a prolonged tonic
response from 15 to 60 min after formalin injection.
DMSO administration induced a significant increase in
the nociceptive behaviour of animals in phase I of the
test, when compared with the CT group (Figure 3), while
no difference was reported between CT and DMSOt. FT: formalin test. DMSO Group: DMSO injected i.p. (2 ml /Kg, i.p.);
AM1241 Group: AM1241 (b) (4 mg/kg, i.p.) dissolved in DMSO injected
i.p. (3 ml/kg); NTG Group: nitroglycerin (dissolved in saline, alcohol and
oup: nitroglycerin (10 mg/kg) and DMSO (2 ml/kg) administered i.p.;
/kg, i.p.) administered i.p.; NTG + AM1241 (b) Group: nitroglycerin
Figure 2 Activity of AM1241 at the tail flick test in naïve rats and in rats treated with nitroglycerin. Data are expressed as percent change
(0%) from baseline ± SEM. In naïve rats, DMSO, used as vehicle, did not show significant effect on latency when compared with baseline levels,
while AM1241 induced a significant increase of latency 60 minutes after its administration. Rats treated with nitroglycerin (NTG) showed hyperalgesia,
demonstrated by the significant reduction in the latency of tail flicking 4 h after its administration when compared with baseline levels. The CT group
did not show significant effect on latency when compared with baseline levels. Both doses of AM1241 failed to modify NTG-induced hyperalgesia.
*p < 0.05 vs baseline.
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or with DMSO, significantly increased the total number
of flinches/shakes in phase II of formalin test, when
compared either to control group (CT) or to DMSO
group (Figure 3). The lower dose of AM1241 (2 mg/Kg)
significantly inhibited nociceptive behaviour induced by
formalin injection only in phase II when compared to
the DMSO group. The higher dose (4 mg/Kg) of the
CB2 agonist significantly inhibited nociceptive behaviour
induced by formalin injection during both phases of
the test when compared with DMSO group. Both doses
of AM1241 proved effective in counteracting NTG-
induced hyperalgesia in phase II, as suggested by the
reduction of the nocifensive behaviour of animal pre-
treated with NTG. Comparison of the 2 mg and
4 mg AM1241 groups with the NTG +AM1241 (2 mg
and 4 mg) groups did not show any significant differ-
ences in phase II of the test.
Discussion
Several lines of evidence have highlighted the import-
ance of cannabinoid-mediated analgesia for nociceptive
processing. Exogenous cannabinoids reduce responsive-
ness to noxious thermal, chemical and mechanical stim-
uli in rats. Cannabinoids induce antinociception by
acting in neuroanatomical regions subserving transmis-
sion and modulation of pain signals, including, the peri-
aqueductal gray (PAG) [33,34] and the basolateral
nucleus of amygdala [35]. The analgesic effect of endo-
cannabinoids can be attributed in part to a neuronal
mechanism based on the activation of CB1 receptors
expressed in primary afferent neurons. Indeed, it has
been clearly demonstrated that CB1 receptors are in-
volved in modulation of pain signals via the inhibition of
the release of neurotransmitters such as γ-aminobutyric
acid (GABA), glutamate, dopamine, noradrenaline and
acetylcholine [36]. Also CB2 receptors appear to contrib-
ute to the analgesic effect, as suggested by theattenuation of pain in animal models of inflammatory
and nociceptive pain [37]. Originally described in im-
mune cells [4], CB2 receptors have been demonstrated
in human peripheral nerves after injury, as well as in
brain regions, i.e. brainstem, which are particularly rele-
vant for nociceptive integration [38-41].
Endocannabinoid deficit may be involved in the patho-
physiology of migraine as supported by an increasing
body of evidence [22,23]. In previous studies, using the
same animal model proposed in the present study, we
have provided data supporting the role of endocannabi-
noids in NTG-induced hyperalgesia [22]. In particular,
we have demonstrated that NTG injection causes specific
changes in endocannabinoids content in discrete cerebral
areas, while the administration of AEA (20 mg kg−1, i.p.), a
CB1/CB2 agonist, reduces NTG-induced c-Fos expression
in the NTC [22].
The analgesic effects derived from selective stimula-
tion of CB1 receptors is well known, but the relevant
side-effects related to the stimulation of CB1 receptors
[11] have limited the clinical development of this thera-
peutic line. Interestingly, CB2 agonists can reduce noci-
ception in several preclinical models of pain without
producing tolerance [9] or central side-effects [11].
Therefore CB2 antagonists seems more attractive as
potential targets for modulating pain.
In the present study, we have shown that activation of
CB2 receptor, by means of AM1241 administration, in-
duces analgesia at both the tail flick and the formalin
tests. These findings are in agreement with behavioural,
electrophysiological and neurochemical studies that showed
the role for CB2 receptor activation in modulating in-
flammatory nociception [40,42-44].
Furthermore, we detected an anti-hyperalgesic effect of
AM1241 when the experimental paradigm was represented
by phase II of formalin test in NTG treated animals, i.e. a
condition of hyperalgesia mediated by the peripheral release
of inflammation mediators and by central modulation.
Figure 3 Activity of AM1241 at the formalin test in naïve rats and in rats treated with nitroglycerin. In the vehicle groups (DMSO and
Control, CT), the injection of formalin resulted in a highly reliable, typical, biphasic pattern of flinches/shakes of the injected paw, being characterized
by an initial acute phase of nociception within the first 5 min, followed by a prolonged tonic response from 15 to 60 min after formalin injection.
DMSO administration induced a significant increase in the nocifensive behaviour of animals only in phase I, when compared with the CT group. No
difference was reported between CT and DMSO groups in phase II. NTG administration, alone or with DMSO, significantly increased the total number
of flinches/shakes in phase II of formalin test, when compared either to CT group or to DMSO group. In naive rats, the lower dose of AM1241
(2 mg/kg) significantly inhibited nocifensive behaviour induced by formalin injection during phase I, while the higher dose (4 mg/Kg) inhibited the
nocifensive behaviour in both phases of the test when compared with DMSO group. In rats treated with nitroglycerin (NTG), both doses of AM1241
significantly reduced the total number of flinches/shakes in phase I of test, when compared to NTG + DMSO group, and phase II of the test when
compared to both NTG and NTG + DMSO groups. Data are expressed as mean ± SEM. ANOVA analysis followed by Tukey’s Multiple Comparison test,
*p < 0.05 vs CT; °p < 0.05 vs NTG; #p < 0.05 NTG + DMSO; §p < 0.05 vs DMSO.
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stimulation of sensorial areas that are outside of the tri-
geminal distribution, which may limit the applicability of
our findings to migraine. However the model seems
quite specific for cephalic pain since we have previously
demonstrated that plantar injection of formalin in rats
induces significant changes in calcitonin gene-related
peptide (CGRP) immunoreactivity in the superficial lam-
inae I and II ipsilateral to the injection side also in theNTC and that systemic NTG administration causes a
reduction in CGRP-imunoreactivity in the NTC, but not
in the lumbar dorsal horns [45]. Taken together with the
demonstrated capability of NTG to induce spontaneous-
like migraine attacks in migraineurs, these findings sug-
gest that NTG-potentiated formalin test is a relevant
model for investigating migraine circuitry. Though so far
unexplained, the observation that a nociceptive stimulus
delivered at the paw level is associated with NTC
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[46], which showed that formalin injection in the paw
induces Fos expression in NTC, and in other brainstem
areas (i.e locus coeruleus) known to be involved in the
modulation of migraine pain [47]. The possible mecha-
nisms underlying NTG-induced hyperalgesia are presently
elusive. However, it is becoming increasingly evident that
NTG exerts its hyperalgesic effect through central and
peripheral mechanisms [15,16]. NTG may induce indeed
a direct hyperalgesic effect via the formation of nitric
oxide (NO) and via CGRP release in the NTC [42,48], or
indirectly via the activation of NOS synthesis at the
meningeal level as a consequence of a sensitization of
the trigeminovascular system [49-51].
CB2 receptors are expressed predominantly, but not
exclusively, outside the CNS [41,42], where they are
localized extensively to cells of the immune system [52].
CB2 receptors have been detected in cultured DRG
neurons and in afferent fibers in the dorsal horn of the
spinal cord [53], which confirms that CB2 receptors are
present in an area that is relevant for the mediation of
the response to the formalin test.
In our experimental paradigm, CB2 receptor activation
may interfere with the mechanisms associated with
NTG-induced hyperalgesia at two levels: central and
peripheral. As regards the central one, Beltramo et al.,
[40] demonstrated that AM1241 reduces capsaicin-
induced CGRP release in dorsal root ganglia (DRG),
confirming that CB2 activation may elicit cause analgesia
by acting not only at non-neuronal peripheral sites but
also at the neural level. Accordingly, the activation of
CB2 receptors reduces spinal fos protein expression and
pain behaviour in a rat model of inflammation [42].
Taken together, these observations suggest that one pos-
sible mechanism through which AM1241 reduces NTG-
induced hyperalgesia is the inhibition of CGRP release
in laminae I and II of the NTC (lower brainstem and
cervical spinal cord) [45], although further studies are
needed to confirm this hypothesis. Indeed, following
NTG administration, CGRP immunoreactivity decreased
steadily in the NTC, whereas substance P immunoreac-
tivity increased transiently [45].
When considering the potential peripheral mecha-
nisms underlying the inhibitory effect of CB2 agonism
upon NTG-induced hyperalgesia, it seems noteworthy
that emerging literature implicates a role for neuroim-
mune interactions in contributing to the development or
maintenance of pathological pain states [54], and that it
has been shown that NTG administration causes a de-
layed meningeal inflammation, as showed by activation
of inducible NO synthases (iNOS) in macrophages of
rodents, and a prolonged cold allodynia and heat hyper-
algesia with a time-course consistent with NTG-induced
migraine attacks [49,55]. Therefore, we suggest thatanother possible site of action for AM1241 is repre-
sented by the dura, where the CB2 agonist may coun-
teract NO-induced activation of macrophages via the
inhibition of NO by iNOS. Indeed, activation of CB2
receptors on non-neuronal cells has been postulated
to suppress the release of inflammatory mediators that
sensitize nociceptors [56]. This hypothesis is partially
supported by the demonstrated interactions between
the endocannabinoid and the nitrergic systems in CB2
signalling. The activation of the CB2 receptor seems
indeed to be associated with a reduced expression of
iNOS [57]. Additionally, CB2 stimulation seems to
suppress the release of pro-inflammatory factors such
as NO and tumor necrosis factor alpha (TNF-α) in
macrophages [58].
A collateral finding of this study is represented by the
increase in nocifensive behavior in phase I of the forma-
lin test following the administration of DMSO. This
finding is partially in agreement with the observations of
Colucci et al. (2008) [59] who showed an increase in the
nocifensive behavior in both phases of the formalin test
when DMSO was applied subcutaneously in the mouse
paw. Conversely, the same study demonstrated an anti-
nociceptive activity when DMSO was administered cen-
trally or intraperitoneally [59]. These results suggest that
DMSO displayed opposite effects on nociception and
inflammation, depending on the route of administration.
DMSO is one of the most common solvents used experi-
mentally to dissolve hydrophobic substances for in vivo
and in vitro purposes. The exact mechanism underlying
DMSO pro-nociceptive activity is not known, but our
findings show that the pro-nociceptive effect observed in
phase I of the formalin test in the DMSO and NTG +
DMSO groups (Figure 3) was counteracted by activation
of CB2 receptors.
Conclusions
The present study lends further support to the thera-
peutic potential in migraine of probes that interfere with
the endocannabinoid system. More specifically, stimula-
tion of CB2 receptors seems promising as it counteracts
NTG-induced hyperalgesia in phase II of the formalin
test and it is theoretically less likely to induce CNS side
effects. However, the impact of long term treatment with
CB2 agonists on their anti-hyperalgesic efficacy and on
their effect on the immune system function remains to
be elucidated.
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